CTLA-4

CTLA-4. Cytotoxic T-lymphocyte-associated protein 4 is a critical immune checkpoint receptor expressed on the surface of T cells. It functions as a potent negative regulator of T cell activation, playing a fundamental role in maintaining immune tolerance and preventing autoimmunity. Its discovery and subsequent therapeutic targeting have revolutionized the treatment of cancer and provided profound insights into immune system regulation.

Structure and function

The protein is a member of the immunoglobulin superfamily and shares structural homology with the co-stimulatory receptor CD28. It exists as a homodimer on the cell surface and binds to the same ligands, B7-1 and B7-2, which are expressed on antigen-presenting cells. However, its cytoplasmic tail contains distinct motifs, including an immunoreceptor tyrosine-based inhibitory motif, that mediate inhibitory signaling. Upon ligand binding, it recruits phosphatases like SHP2 and PP2A to the immunological synapse, effectively dampening T cell receptor signaling and interleukin-2 production.

Role in immune regulation

Its primary role is to terminate T cell responses and promote immune tolerance. During the normal course of an immune response, CD28 provides a positive signal for T cell proliferation, while it delivers a competing negative signal that acts as a crucial braking mechanism. This dynamic balance prevents excessive lymphocyte activation that could lead to tissue damage. Its function is essential for the activity of regulatory T cells, where it contributes to their suppressive function. Genetic deficiencies in mice, as studied in the Jackson Laboratory, result in fatal lymphoproliferative disease, highlighting its non-redundant role.

Clinical significance

Dysregulation of this pathway is implicated in numerous autoimmune diseases. Single-nucleotide polymorphisms in the gene are associated with increased susceptibility to Graves' disease, Hashimoto's thyroiditis, type 1 diabetes, and celiac disease. Conversely, many tumors exploit this pathway by upregulating B7 ligands to engage the receptor and suppress anti-tumor immunity, leading to immune evasion. This makes the pathway a major target for cancer immunotherapy, as blocking it can reinvigorate the host response against malignant cells.

Discovery and history

The protein was independently discovered in 1987 by research teams led by Pierre Golstein in France and by Jeffrey Bluestone and James Allison in the United States. Initial work characterized it as a molecule induced upon T cell activation. The pivotal functional understanding came from studies by James Allison and colleagues, who demonstrated that antibody-mediated blockade could enhance T cell responses and reject established tumors in mice. This foundational research, conducted at institutions like the University of California, Berkeley and the Memorial Sloan Kettering Cancer Center, laid the groundwork for a new class of therapeutic agents.

Therapeutic applications

The clinical translation of this research culminated in the development of ipilimumab, a monoclonal antibody that blocks the receptor. Ipilimumab was approved by the U.S. Food and Drug Administration in 2011 for the treatment of metastatic melanoma, marking the first immune checkpoint inhibitor to reach patients. This approval, following trials led by organizations like the National Cancer Institute, validated the concept of immune checkpoint blockade. The success of this approach earned James Allison a share of the 2018 Nobel Prize in Physiology or Medicine. Subsequent combination therapies with other inhibitors, such as those targeting PD-1, have become standard in treating lung cancer, renal cell carcinoma, and other malignancies.

Category:Immune system Category:Proteins Category:Oncology